The worldwide rights expansion strengthens MIRA's ability to pursue global licensing or partnership discussions for Ketamir-2. Monitor for Phase 2a protocol submission to FDA and potential partnership announcements as key catalysts. The stock's small cap and early-stage nature mean binary risk remains high despite this positive IP development.
Price Chart
Executive Summary
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide rights and added international patent filings across 10 major markets. The amendment did not change core economic terms, and the company is advancing toward Phase 2a development in chemotherapy-induced peripheral neuropathy (CIPN). This is a positive strategic step for a clinical-stage biotech with a $41M market cap, but no financial terms or near-term revenue catalyst were disclosed.
Key Financial Metrics
Key Facts
- Expanded exclusive licensed territory for Ketamir-2 from US/Canada/Mexico to worldwide rights across all countries with patent rights
- Expanded patent portfolio now includes filings in US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea
- Core economic terms (royalty obligations and other financial consideration) were not materially modified
- Company is advancing toward planned Phase 2a development in CIPN with positive Phase 1 results across 56 healthy volunteers
- Ketamir-2 is not classified as a controlled substance per DEA determination
- Market cap is $41M with 86% analyst bullish rating (6 Buy/Strong Buy, 1 Hold)
Financial Impact
No financial terms disclosed; amendment did not modify core economic terms of original license agreement
Risk Factors
- Ketamir-2 has not been approved by FDA for any indication; safety and efficacy not established
- Clinical-stage biotech with no approved products or disclosed revenue
- Phase 2a development carries inherent clinical trial risk
- No financial terms disclosed limits ability to quantify value of expanded rights
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025335 |
| Document: 0001493152-26-025335-index-headers.html | 0001493152-26-025335 |
| Document: 0001493152-26-025335-index.html | 0001493152-26-025335 |
| Document: 0001493152-26-025335.txt | 0001493152-26-025335 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5588 (−11.16%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5588 (−11.15%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5588 (−26.41%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5588 (−26.41%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5588 (−35.02%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5588 (−17.61%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5588 (−39.56%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5588 (−41.48%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5588 (−42.87%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5588 (−42.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers